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Abstract Background: Prolonged
administration of benzodiazepines
and/or opioids to children in a pe-
diatric intensive care unit (PICU)
may induce physiological depen-
dence and withdrawal symptoms.
Objective: We reviewed the lit-
erature for relevant contributions
on the nature of these withdrawal
symptoms and on availability of
valid scoring systems to assess the
extent of symptoms. Methods: The
databases PubMed, CINAHL, and
Psychinfo (1980–June 2006) were
searched using relevant key terms.
Results: Symptoms of benzodi-
azepine and opioid withdrawal can
be classified in two groups: central
nervous system effects and autonomic
dysfunction. However, symptoms of
the two types show a large overlap
for benzodiazepine and opioid with-
drawal. Symptoms of gastrointestinal
dysfunction in the PICU population
have been described for opioid with-
drawal only. Six assessment tools
for withdrawal symptoms are used
in children. Four of these have been
validated for neonates only. Two in-
struments are available to specifical-
ly determine withdrawal symptoms
in the PICU: the Sedation With-
drawal Score (SWS) and the Opi-
oid Benzodiazepine Withdrawal
Scale (OBWS). The OBWS is the
only available assessment tool with
prospective validation; however, the
sensitivity is low. Conclusions:
Withdrawal symptoms for benzodi-
azepines and opioids largely overlap.
A sufficiently sensitive instrument for
assessing withdrawal symptoms in
PICU patients needs to be developed.
Keywords Withdrawal symptoms ·
Opioids · Benzodiazepines · Depend-
ence · Tolerance · Pediatric intensive
care unit
Introduction
Ventilated, critically ill children commonly receive seda-
tive and analgesic drugs to ease their mental burden, anx-
iety and pain, induced by frightening or painful interven-
tions and environmental factors in the pediatric intensive
care unit (PICU). Intravenous opioids (such as morphine
and fentanyl) and benzodiazepines (such as midazolam)
are the most commonly used drugs for this purpose [1, 2].
Tolerance and physiological dependence may develop dur-
ing long-term administration of opioids and/or benzodi-
azepines and are risk factors contributing to withdrawal
symptoms precipitated by too rapid tapering or cessation
of these medications [3]. Tolerance is defined as a decrease
in a drug’s effect or the need to increase the dose to achieve
the same effect [3, 4]. Physiological dependence is the re-
quirement for continued administration of a sedative or
analgesic to prevent signs of withdrawal [4]. Psychologi-
cal dependence is the need for a substance because of its
euphoric effects and is encountered in the care and treat-
ment of drug addicts [5]. Discontinuation of medication in
dependent patients leads to symptoms of withdrawal [5].
Most of our knowledge on tolerance and withdrawal
symptoms has been derived from research in newborns of
drug-addicted mothers [6, 7] and from the literature on
adult opium-addicted patients. Benzodiazepine withdrawal
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is also reported in adult psychiatric and drug-addicted
populations [8–10]. Two retrospective and one prospec-
tive randomized controlled trial have been reported on
opioid and/or benzodiazepine withdrawal after long-term
administration of analgesics or sedatives in the adult ICU
setting [11–13]. The reported incidence of withdrawal
syndrome in adult ICU patients ranges from 32.1% (9/28)
to 100% [11, 12]. Each of these studies used a different
assessment tool, however, which makes it difficult to
describe symptoms in a uniform manner. Symptoms in
these patients are mostly agitation, irritability, anxiety,
insomnia, tachycardia, hypertension, and sweating. High
total doses and exposure to medication for longer than
7 days are risk factors for developing withdrawal symp-
toms in the adult ICU. This knowledge may serve to gain
a better insight into problems of tolerance, dependence,
and withdrawal in pediatric intensive care, which are still
insufficiently recognized [14]. Recognition of withdrawal
in PICU patients is difficult because the symptoms may
strongly overlap clinical signs of inadequate sedation,
such as agitation, anxiety, and movement disorder. An
objective instrument to establish withdrawal symptoms
of critically ill children in clinical practice is necessary
to establish severity and course of the symptoms and to
evaluate efficacy of withdrawal treatment.
This review of the literature addresses two questions.
First, what withdrawal symptoms resulting from long-term
use of sedatives (opioids and/or benzodiazepines) in crit-
ically ill children in a PICU have been described and might
be useful in an assessment tool? Second, are there any vali-
dated, reliable tools to assess withdrawal symptoms in chil-
dren in a PICU in clinical practice?
Methods
The databases PubMed, CINAHL, and Psychinfo were
searched for relevant literature on (a) benzodiazepine
and opioid withdrawal symptoms or (b) assessment
tools for withdrawal symptoms. Time limits were set at
January 1980 and May 2006. Only articles published
in English or Dutch were included in the study. The
following exploded MeSH terms were used: “withdrawal
symptoms”, “abstinence syndrome”, “tolerance” with
“opioid”, “benzodiazepine”, and with “PICU”, “critically
ill children”, or with “assessment tool”, “scoring system”.
The age limits were set at 0 and 16 years. Preterm neonates
(< 37 weeks gestation) and neonates of addicted mothers
were excluded because generally they are not admitted
to a PICU. A first search for reviews retrieved seven
relevant articles which were used to delineate the domain
of withdrawal symptoms [3–5, 7, 15–17]. Two of these
reviews relate to patients in a neonatal ICU [7, 15]. They
were nevertheless included because PICUs admit surgical
neonates as well. Also, these two reviews did not focus on
neonates of addicted mothers.
In total, abstracts of 53 articles were evaluated. Ar-
ticles on withdrawal symptoms had to meet two criteria
for inclusion in this review: describing a study of benzo-
diazepine and/or opioid withdrawal symptoms and relat-
ing to the age restriction. In total 20 articles, either case
studies, retrospective or prospective studies, met these cri-
teria [18–37]. Table 1 lists the studies from which the with-
drawal symptoms were derived, grouped by type of medi-
cation, study design, and methodological quality. Studies
on assessment tools for identifying withdrawal symptoms
had to meet the following criteria: (a) the tool should be
aimed at identifying symptoms of benzodiazepine and/or
opioid withdrawal; (b) the tool should be appropriate for
children. Two articles met these criteria [17, 29].
Results
Withdrawal symptoms
Opioid withdrawal symptoms
Clinical signs of opioid withdrawal in newborns include
those of the neurological system (high-pitched crying,
irritability, increased wakefulness, hyperactive deep ten-
don reflexes, increased muscle tone, tremors, exaggerated
Moro-reflex, seizures, intraventricular hemorrhage), those
of the gastrointestinal tract (poor feeding, uncoordinated
and/or constant sucking, vomiting, diarrhea, dehydration),
autonomic signs (increased sweating, nasal stuffiness,
fever, mottling), and others (poor weight gain, increased
rapid-eye movement sleep, skin excoriation) [6, 15].
Symptoms of opioid withdrawal in newborns of drug-
addicted mothers are generally divided into three main
groups: overstimulation of the central nervous system
(CNS), gastrointestinal dysfunction, and autonomic dys-
regulation or sympathetic hyperactivity [4, 15, 38]. Table 2
lists the described signs and symptoms of withdrawal in
children relating to either opioids or benzodiazepines,
or combined use, broken down for these three groups.
(a) Common manifestations of CNS overstimulation are:
tremors, increased muscle tension, anxiety, restlessness,
irritability, and insomnia [21, 23–27, 29, 30, 32, 33]. In
addition, Lane et al. [26] and French and Nocera [30]
described the development of choreoathetoid movements
as a withdrawal symptom of fentanyl administration
in five children and one child, respectively, as well
as intermittent muscle contractions and uncontrolled
movements after long-term use of fentanyl. (b) The most
frequent gastrointestinal symptoms of opioid withdrawal
are vomiting and diarrhea [23–25, 27, 29, 32]. Carnevale
and Ducharme [32] in addition reported reduced oral
intake. (c) Autonomic phenomena are: fever, perspiration,
sneezing, yawning, increased heart rate, and blood pres-
sure [23–25, 29, 30]. Note that increases in heart rate and
blood pressure should be seen in relation to the normal
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values for the child’s age and disease. In summary, the
clinical signs of opioid withdrawal in children (Table 2)
are largely congruent with those in newborn babies of
drug-addicted mothers.
Benzodiazepine withdrawal symptoms
Classical characteristics of benzodiazepine withdrawal
described for the domains of adult psychiatry and drug ad-
dicts care are: severe anxiety, involuntary muscle tremors,
confusion, insomnia, perception disorders, depression,
and generalized convulsions [4, 9]. In contrast to opioids,
a systematic classification of benzodiazepine withdrawal
symptoms is not available in the literature. For the sake of
uniformity, however, the grouping for opioid withdrawal
symptoms will be used here as well. Table 2 lists the
observed withdrawal symptoms for benzodiazepines.
Strikingly, most symptoms have been described on the
basis of single case-reports and case series with small
numbers of patients. Only two articles describe larger
patient groups of 40 and 53 patients, respectively [28, 31].
Symptoms observed in these two studies were different,
however, and the used observation forms included no
more than five and seven symptoms, respectively. These
qualitative and quantitative limitations, notably in the case
studies, provide only limited insight into the symptoms
of benzodiazepine withdrawal. The benzodiazepines
studies were all of a descriptive nature, in contrast to
the opioids studies. (a) Regarding CNS overstimulation,
Sury et al. [22] in a case-report first described withdrawal
symptoms resulting from long-term use of midazolam in
Table 2 Described signs and symptoms of benzodiazepine and opioid withdrawal in children
Central nervous system irritability Gastrointestinal dysfunction Autonomic dysfunction
Opioids Increased muscle tone Vomiting Tachypnea
Myoclonus Poor feeding Yawning
Ataxia Diarrhea Sneezing
Abnormal movements Hypertension
Pupil dilation (> 4 mm) Mottling
High pitched crying
Benzodiazepines Muscle twitching Frequent suction required
Inconsolable crying
Grimacing
Jitteriness
Visual, auditory hallucinations
Disorientation
Seizures
Movement disorder
Opioids and Tremor Fever
benzodiazepines Anxiety Sweating
Agitation/crying Tachycardia
Irritability
Insomnia/sleep disturbance
Choreoathetoid movements
(of upper extremities)
children. Three children aged 4, 11, and 12 years received
midazolam as a sedative for 7, 14 and 17 days, respec-
tively. Within 24 h after discontinuation they showed signs
of (visual) hallucinations, irritability, confusion, restless-
ness/agitated behavior and generalized convulsions. These
are all manifestations of CNS overstimulation. Other
studies report tremors, anxiety, agitation, restlessness,
inconsolable crying, muscle twitching, and myoclonic
movements of the extremities [18, 19, 21, 28, 29, 31–33].
(b) Regarding sympathetic hyperactivity, a case study
of two children observed tachycardia and fever as ben-
zodiazepine withdrawal reactions [19]. Others observed
perspiration, insomnia and severe coughing [29, 31].
(c) Regarding gastrointestinal dysfunction, one case study
of a 14-day-old newborn reported vomiting caused by
a distended stomach resulting from swallowing air [19].
This single case report provides insufficient evidence to
include this symptom as a benzodiazepine withdrawal
symptom. Dysfunction of the gastrointestinal tract as
a symptom of benzodiazepine withdrawal has not been de-
scribed in adults [9, 12]. In summary, the major symptoms
of benzodiazepine withdrawal in children are anxiety,
tremors, and other involuntary muscle movements, irri-
tability, perspiration and insomnia. These correspond to
the classical manifestations of benzodiazepine withdrawal
in adults [4, 9].
Combined benzodiazepine-opioid withdrawal symptoms
Differences between opioid and benzodiazepine with-
drawal symptoms are marginal [4]. Symptoms associated
1401
with CNS overstimulation and sympathetic hyperactivity
largely overlap after long-term use of benzodiazepines
or opioids in children (see Table 2). However, benzodi-
azepine withdrawal is not associated with symptoms of
the gastrointestinal tract [4, 12]. The Moro-reflex is used
as an opioid withdrawal symptom in neonates [6, 15].
The Moro-reflex disappears between the ages of 1 and
3 months and is therefore never observed in children older
than 3 months. The study by Franck et al. [29] included
1.5- to 28 month-old children, and the Moro-reflex was
one of the items in their assessment tool. In view of
the age limitation we feel it is not feasible to use this
symptom as a withdrawal symptom for PICU patients [3].
Several studies found it hard to determine whether the
withdrawal symptoms were specifically caused by benzo-
diazepines dependence because in these studies opioids
(morphine, fentanyl) were administered for sedation as
well [18, 21, 28, 29, 33]. This illustrates the practical
limitation for describing specific benzodiazepine-related
withdrawal symptoms in the PICU. From clinical ex-
perience we know that benzodiazepines and opioids are
usually administered in combination for sedation and
analgesia, from several days to weeks as reflected in the
literature [1, 38]. Given the overlap in symptoms, it is
hard to ascribe withdrawal symptoms to either opioids or
benzodiazepines [21, 29, 32].
Incidences and influencing factors of benzodiazepine
and opioid withdrawal
Knowledge on the incidences of benzodiazepine and
opioid withdrawal symptoms in general as well as the
frequencies of the separate phenomena provide clues
for the symptoms to be used in an assessment tool.
Furthermore, knowledge of possible risk factors for the
development of withdrawal symptoms enables physicians
and nurses to identify patients at risk. Only five articles
describe incidences and influencing factors for the devel-
opment of withdrawal symptoms after long-term use of
benzodiazepines or opioids in children [27, 28, 31].
Incidence
Fonsmark et al. [31] in a retrospective study found that
14 of 40 (35%) of sedated children (6 months–14 years)
developed withdrawal symptoms. A prospective study
of abrupt discontinuation of midazolam in critically ill
children (0–11 years) reports adverse side effects in 17%
of the 53 patients [28]. Opioid withdrawal symptoms
were seen in 13/23 (57%) children aged 0–22 months
after prolonged continuous fentanyl administration [27].
Methods differed between these three studies. Katz
et al. [27] used the Neonatal Abstinence Score (NAS)
developed by Finnegan et al. [6] which has only been
validated for use in newborns. Hughes et al. [28] and
Fonsmark et al. [31] did not use existing tools but
recorded withdrawal symptoms through self-developed
observation lists. These lists included a limited number
(five) of behavioral items [28, 31]. Fonsmark et al. [31]
included “sweating” as a physiological item. The au-
thors did not provide data on reliability and validity of
their observation lists [28, 31]. Patients who required
extracorporeal membrane oxygenation (ECMO) therapy
comprised a specific PICU population. In these popula-
tions opioid withdrawal (NAS > 8) was seen in 9–57% of
children [35, 37].
Influencing factors
Various authors have shown that dosing and duration
of benzodiazepines or opioids influence development of
withdrawal symptoms [27, 30, 31]. Fonsmark et al. [31]
found a total midazolam dose higher than 60 mg/kg to be
associated with the occurrence of withdrawal symptoms.
Katz et al. [27] found a total fentanyl dose of 2.5 mg/kg
or higher or a fentanyl infusion for at least 9 days to
result in withdrawal symptoms in 100% of cases. Arnold
et al. [35] found that neonates receiving ECMO therapy
with total doses greater than 1.6 mg/kg fentanyl or an
ECMO duration of longer than 5 days had a significantly
greater incidence of withdrawal symptoms reflected
by the NAS. In another study in ECMO patients the
authors demonstrated that neonates who received total
fentanyl doses higher than 1.2 mg/kg were 13 times more
likely to experience opioid withdrawal after ECMO [37].
Evaluation of the various studies reveals that children
in a PICU receiving benzodiazepines and/or opioids
for 5 days or longer are at risk for developing with-
drawal symptoms [17, 23–25, 27–31]. Benzodiazepine
and/or opioid withdrawal symptoms may occur if these
medications are abruptly stopped or tapered off too
rapidly in children showing physical dependence [38].
Manifestations typically occur 8–48 h after discontinua-
tion.
Systematic clinical assessment of withdrawal symptoms
The task of assessing seriously ill children for signs of
tolerance, dependence, or withdrawal notably falls to
the pediatric critical care nurse [4]. This requires par-
ticularly awareness, knowledge of and insight into these
phenomena. For clinical purposes a validated and reliable
assessment tool would be very helpful. Table 3 provides
details of six assessment tools for withdrawal symptoms
in children that are used in practice and in research. Four
of these were developed and validated for application in
neonates after long-term use of opioids or in newborn ba-
bies of drug-addicted mothers [6, 39–41]. The most widely
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used is the NAS [6]. These four instruments have not
been validated for use in older children. However, in the
absence of a validated and reliable instrument for children,
several authors have opted for the NAS [24, 25, 27, 30].
Other authors designed observation checklists themselves,
including 5–13 symptoms [25, 38, 31]. These obser-
vation checklists have not been properly validated for
use in children [25, 31]. Two recent articles describe
assessment tools for observing withdrawal symptoms
after long-term use of opioids and/or benzodiazepines
in children in a PICU: the Sedation Withdrawal Score
(SWS) [17] and the Opioid Benzodiazepine Withdrawal
Scale (OBWS) [29].
Sedation Withdrawal Score
The SWS includes 12 symptoms of withdrawal (see
Table 3) and was developed in 2004 by Cunliffe et al. [17].
Each symptom is scored on a three-point scale, ranging
from absent (0), mild (1), to severe (2). Thus a maximum
score of 24 is possible. The authors provide instructions
for the regimen for decreasing sedatives based on cutoff
points. However, a justification for these cutoff points is
not given. The authors consider the SWS to be clinically
sensitive in detecting abstinence in a child of any age with
signs of withdrawal from sedatives and/or opioids [17].
However, data on sensitivity, specificity, validity, and
reliability are lacking.
Opioid and Benzodiazepine Withdrawal Scale
The OBWS is a 21-item checklist with 16 withdrawal
items for determining frequency and severity of with-
drawal symptoms in children (see Table 3) [29]. Franck
et al. [29] tested the predictive validity of the OBWS
by performing 693 assessments in 15 children aged
6 weeks–28 months. Sensitivity of the OBWS at scores
8 (cutoff) or higher was 50%, which implies that the
scale is not better than chance prediction. Specificity was
87%, which implies that the scale rightly classifies 87%
of the children without withdrawal symptoms. The pre-
dictive value expressed in terms of positive and negative
likelihood ratio, 4.0 and 0.57, respectively, is moderate
for a diagnostic instrument. The interrater reliability was
higher than 0.8; the agreement procedure, however, was
not published. Neither age range nor diagnoses of the
patients in this study are representative for a general PICU.
Finally, including the Moro-reflex is questionable in view
of the inherent age restriction, and reduces the scale’s
content validity. In summary, although both instruments
include relevant withdrawal symptoms associated with
benzodiazepine and/or opioid withdrawal in children, we
feel that psychometric issues of the measurements have
been given insufficient attention.
Discussion and conclusion
Nurses and physicians could give more priority to the
observation and treatment of withdrawal symptoms in
children in a PICU. This literature study describes observ-
able withdrawal symptoms related to benzodiazepines and
opioids use in children in a PICU. It appears that vomiting
cannot be included as a symptom of benzodiazepine
withdrawal in this population [4]. The same is true for
the hyperactive Moro-reflex as a symptom of opioid
withdrawal, given the age limitation [27]. Furthermore,
withdrawal symptoms for benzodiazepines and opioids
had a large overlap for symptoms such as agitation, anx-
iety, tremors, insomnia, fever, sweating, and tachycardia.
Symptoms such as seizure and hallucinations have been
described only as benzodiazepine withdrawal in PICU
patients.
As clinical practice tends to combine medication
from both groups, symptoms cannot easily be ascribed
to either group. Several authors studied only either ben-
zodiazepine or opioid withdrawal symptoms in patients
who received both medications [25, 27, 28, 31]. Then it
was not possible to determine whether the withdrawal
symptoms were specifically caused by benzodiazepine or
opioids because in these studies additional benzodiazepine
or opioids were administered for sedation as well. For
treatment and management purposes we should preferably
distinguish between withdrawal symptoms caused by
weaning of benzodiazepines or opioids. Therefore assess-
ment tools should be sensitive enough to discriminate
between benzodiazepine and opioid related withdrawal
symptoms [3, 24, 42]. Generalization of the identified
withdrawal symptoms is hampered by the fact that most
are based on case series and case reports and consequently
on small numbers of patients. Furthermore, most studies
considered only few withdrawal symptoms. Thus repre-
sentative incidence numbers based on the full spectrum of
withdrawal symptoms are lacking.
In this review high total doses, duration of opioid,
and/or benzodiazepine infusion and ECMO therapy are
described as risk factors in developing withdrawal symp-
toms in PICU patients. These factors are also described
in adult studies [11, 12]. The diagnosis of withdrawal in
patients must be made carefully. Withdrawal symptoms
vary from patient to patient in number, severity and pre-
sentation. However many PICU patients show relatively
subtle clinical symptoms that can easily be confused with
responses to other factors in the PICU. Symptoms such as
agitation, anxiety, insomnia, irritability, fever, tachycardia,
hypertension, and sweating are also an expression of
inadequate sedation or pain management, ventilator dis-
tress, infection, noisy environment, paradoxical reactions,
or delirium [43–47]. These key confounders may mask
withdrawal symptoms. With Tobias [3], we maintain that
the diagnosis of withdrawal symptoms remains one of
exclusion. For example, fever or vomiting should never
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be attributed to withdrawal until other possible causes are
excluded. Key confounders must be excluded as well. We
feel that the occurrence of withdrawal symptoms must be
time-related to a decrease or cessation of benzodiazepines
and/or opioids.
Strategies to reduce the incidence of withdrawal
symptoms begin by making efforts to reduce the total
doses of benzodiazepines and/or opioids administered.
Based on a few prospective studies several authors rec-
ommend a daily tapering rate of 10–20% for children
who receive benzodiazepines and/or opioids for more
than 5–7 days [23–25, 29]. This strategy did not result,
however, in the absence of withdrawal symptoms. Adult
sedative and analgesic guidelines recommend that daily
dose decrements of opioids should not exceed 5–10% in
high-risk patients [48]. Playfor et al. [49] support use of
this practice in the PICU in spite of the fact that there is
little evidence for its efficacy. Several studies evaluating
withdrawal symptoms, incidence and risk factors in the
PICU used an assessment tool (NAS) not validated for
use in children in a PICU. The results of these studies
therefore may not be reliable, and symptoms may have
been overlooked. Most of these scoring systems (four of
six, see Table 3) were developed to assess the severity of
withdrawal in infants and drugs-addicted mothers. They
have some limitations, however. First, they were developed
to assess neonatal behavior and opioid withdrawal [3, 49].
Certain reflexes such as the Moro can only be judged in
children below 3 months, and this implies that they cannot
be used in the total PICU age group. Second, cutoff points
for other patients than newborns of addicted mothers are
not defined. For these reasons the NAS is less useful in
PICU patients because most receive both opioids and
benzodiazepines.
The available literature demonstrates that a good
assessment tool for clinical use in children is lacking [49].
A good assessment tool can be defined as a tool, which
is valid reliable, and clinically useful. This means that
a cutoff point is established, and that the tool shows sen-
sitivity to change [50, 51]. Furthermore Franck et al. [29]
stated that clinical utility may be improved with fewer
items and longer intervals between assessments. The
OBWS displays moderate validity and includes an item
that is not representative for the target population. We
agree with Cunliffe et al. [17] that the SWS includes
clinically relevant items for the observation of withdrawal
symptoms in children on the basis of the described with-
drawal symptoms in our literature study. However, it lacks
a good methodological foundation. The OBWS is the only
available assessment tool with prospective validation;
however, its sensitivity is low. In general, assessment
tools must preferably be tested in a multicenter study with
a larger patient population and an extensive patient mix.
The criterion validity can be tested using an independent
expert’s opinion because there is no gold standard for
opioid and benzodiazepine withdrawal in children. Fur-
ther assessments should be carried out before and after
tapering off of opioids or benzodiazepines. At least key
confounders that mask withdrawal must be excluded.
In conclusion, the OBWS can be feasible for assessing
benzodiazepine and/or opioid withdrawal symptoms in
children in a PICU when additional validation has been
completed.
This review clearly provides directions for further
research. First, quantification of withdrawal symptoms in
children based on the symptoms and signs listed in this
review is needed to clearly define the spectrum of with-
drawal in PICU patients. Second, an adapted withdrawal
assessment tool based on this quantification needs to be
developed and psychometric issues must be tested before
application in the PICU population.
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